ImClone announced that late-stage study data showed that first-line treatment with Erbitux (cetuximab) plus standard chemotherapy significantly increased overall survival by about five weeks in patients with advanced non-small cell lung cancer (NSCLC), compared with chemotherapy alone. The results were presented at the American Society of Clinical Oncology (ASCO) meeting this weekend. To put things [...]
Entries Tagged as 'lung cancer'
Erbitux extends overall survival by 5 weeks in lung cancer
June 2nd, 2008 · No Comments · cancer, company news, competitive intelligence, lung cancer, market intelligence, market trends, oncology
Tags:
Study showed Alimta improved survival in certain types of Non-Small Cell Lung Cancer
May 28th, 2008 · No Comments · NSCLC, cancer, competitive intelligence, lung cancer, market intelligence, market trends, oncology
The type of non-small cell lung cancer (NSCLC) patients have may now influence their treatment regimen and, in turn, survival outcome according to the results of a major study published online in the Journal of Clinical Oncology. NSCLC is the most common type of lung cancer and represents 85 to 90 percent of all lung [...]
Tags: